Serevent Inhaler CFC-free

Nchi: Singapoo

Lugha: Kiingereza

Chanzo: HSA (Health Sciences Authority)

Viambatanisho vya kazi:

Salmeterol (as Xinafoate)

Inapatikana kutoka:

GLAXOSMITHKLINE PTE LTD

ATC kanuni:

R03AC12

Kipimo:

25mcg/actuation

Dawa fomu:

AEROSOL, METERED

Njia ya uendeshaji:

RESPIRATORY (INHALATION)

Dawa ya aina:

Prescription Only

Viwandani na:

Glaxo Wellcome Production

Idhini ya tarehe:

2007-06-25

Taarifa za kipeperushi

1

_SEREVENT_™ INHALER CFC-FREE 
SALMETEROL XINAFOATE 

QUALITATIVE AND QUANTITATIVE COMPOSITION 
Pressurised metered-dose inhaler delivering 25 micrograms of
salmeterol as salmeterol 
xinafoate per actuation through the mouthpiece of the actuator.  In
addition to salmeterol 
xinafoate, the inhaler also contains the chlorofluorocarbon (CFC)-free
propellant 
Norflurane (also known as HFA 134a or 1,1,1,2-tetrafluoroethane). 
PHARMACEUTICAL FORM 
Pressurised inhalation, suspension. 
Each canister contains at least 120 actuations. 
CLINICAL PARTICULARS 
INDICATIONS 
_SEREVENT_, as twice daily regular treatment, can replace a
short-acting (four hours) 
inhaled bronchodilator (e.g. salbutamol), when it is required more
than once a day, or an 
oral bronchodilator (e.g. salbutamol, theophylline).
 However, _SEREVENT_ is not a 
replacement for oral or inhaled steroids, its use is complementary to
them.  Patients must 
be warned not to stop therapy or reduce it without medical advice,
even if they feel better 
on _SEREVENT_.  
Bronchodilators should not be the only or the main treatment in
patients with severe or 
unstable asthma.  Severe asthma requires regular medical assessment
as death may occur.  
Patients with severe asthma have constant symptoms and
frequent exacerbations, with 
limited physical capacity and PEF values below 60% predicted at
baseline with greater 
than 30% variability usually not returning entirely to normal after a
bronchodilator.  
These patients require high dose inhaled (e.g. greater than 1 mg/day
beclomethasone 
dipropionate) or oral corticosteroid therapy.  With optimal
background steroid therapy, 
_SEREVENT_ can offer additional symptomatic treatment.  Sudden
worsening of symptoms 
may require increased additional dosage which should be administered
under medical 
supervision. 
•  ADULTS 

2
_SEREVENT_ provides long-lasting (12 h) bronchodilation in
reversible airways 
obstruction due to asthma, chr